Immix Biopharma, Inc. (IMMX) vs ProKidney Corp. (PROK)

A side-by-side comparison of Immix Biopharma, Inc. and ProKidney Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

IMMX

Immix Biopharma, Inc.

$524M

$9.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

PROK

ProKidney Corp.

$538M

$1.60HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — IMMX vs PROK

growth of $100 · dividends reinvested · last 5y

IMMX +176.0% (+22.5%/yr)PROK -83.9% (-30.6%/yr)IMMX compounded faster over this window

Log scale — wide-divergence pair

IMMX PROK

IMMX vs PROK: by the numbers

•PROK is the larger company ($538M vs $524M market cap).
•Both run net losses; IMMX's is the smaller (0.00% vs -10599.76% net margin).

Metrics side by side

Valuation

Metric	IMMX	PROK
P/S ratio	N/A	657.71
P/B ratio	2.29	N/A

Profitability

Metric	IMMX	PROK
Gross margin	0.00%	100.00%
Operating margin	0.00%	-18477.83%
Net margin	0.00%	-10599.76%
ROE	-17.44%	N/A
ROIC	-18.20%	-78.31%

Growth (annualized)

Metric	IMMX	PROK
Total return CAGR (5Y)	N/A	-30.65%

Go deeper

Full IMMX analysis Full PROK analysis Interactive comparison tool

Dig into the metrics

Immix Biopharma ROE ProKidney ROE Immix Biopharma operating margin ProKidney operating margin Immix Biopharma revenue growth ProKidney revenue growth Immix Biopharma free cash flow ProKidney free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.